Company intelligence / Profile preview

CardioPep Pharma

Hannover, Lower Saxony, Germany

Ownership: Private
Development stage: Other

Overview

CardioPep Pharma is a German clinical-stage biotechnology company focused on developing innovative peptide-based therapeutics for cardiovascular and renal diseases. The company's research is centered on the natriuretic peptide system, leveraging the expertise of its founders who were instrumental in the discovery of Atrial Natriuretic Peptide (ANP). Its lead candidate, M-ANP, is a designer peptide engineered to provide enhanced cyclic GMP activation with improved stability and a favorable safety profile compared to native peptides. CardioPep targets indications such as chronic heart failure and resistant hypertension, aiming to improve outcomes for patients with cardiorenal syndrome.

Therapeutic areas: CardiovascularNephrology
Modalities: PeptidesBiologic
Industry: Biotech

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on CardioPep Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioPep Pharma.

Explore the full profile